Sinaptica has won a second patent by the USPTO, granting protection for its novel Gen2 dual-stimulation modality, combining electrical and magnetic stimulation.

This patent covers the method of enhancing memory by concurrently stimulating any functional brain network related to memory using a synergistic combination of tACS + TMS.

Based on its remarkable ability to boost long-term associative memory in healthy normals by 60-80% (see Phase 1 POC study), our Gen2 device is currently being tested in a multicenter Phase 2 study in early-stage Alzheimer's (interim readout est. Q1-26).  

If successful, triples system capacity-- designed as a faster, seamless plug-and-play upgrade to our Gen1 installed base with the potential for further improving upon the efficacy achieved in our Phase 2 studies. 

This is an exciting new addition to Sinaptica's growing IP portfolio and part of a broader vision to cover the entire spectrum from performance enhancement, memory preservation, and dementia prevention to treating Alzheimer’s.  

The team intends to further expand the scope of this new patent grant beyond memory enhancement into neurodegenerative disease and other related areas through pursuing additional continuation filings.

Latest one-pager and pitch deck